Crisaborole 99% white powder 906673-24-3 Gentiopicroside High quality HuaMan

• 
  
• Product Feature:
  
•  

• • Product Name	Crisaborole CAS 906673-24-3 bulk Crisaborole powder
    Appearance	white powder
    CAS	906673-24-3
    Assay	99%
    Keywords	Pharmaceuticals Crisaborole;Crisaborole Chemical Raw powder;Crisaborole
    Shelf Life	24 months when properly stored
    Storage	Keep in a cool, dry, dark location

    
    

    What is  Crisaborole ? Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole is indicated for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.

    
    Function of  Crisaborole

    Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole is indicated for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.

    Application of  Crisaborole
    
    Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole is indicated for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.

    
    

    Introduction:

    Criborole (AN2728) is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor. It was first developed by Anacor Pharmaceuticals. In December of the same year, the US FDA approved Criborone (AN2728) ointment (2% or 5%) for the topical treatment of patients over 2 years old. Severe to moderate atopic dermatitis, marketed under the trade name Eucrisa. Product advantages: The biggest advantage of criborole is that it is a small-molecule non-hormonal drug, which can achieve a combination of therapeutic effect and comfort, and even has almost no side effects for some patients. It is the first topical dermatology drug to enter the list of urgently needed new drugs in clinical practice. It can be said that the launch of criborole has filled the treatment needs of Chinese children and adults with atopic dermatitis, breaking the current situation of no new products in the field of topical non-hormonal anti-inflammatory for more than 10 years, which is of epoch-making significance.

    Market outlook:

    Criborole was developed by Anacor, and Pfizer acquired Anacor at a high price. In December 2016, Criborole was approved by the US FDA, becoming the first new drug approved by the US FDA for the treatment of atopic dermatitis (AD) in the past 15 years. molecular entities. In July 2020, Criborone ointment was approved by Chemicalbook in China, becoming the first and only hormone-free PDE-4 inhibitor suitable for the treatment of mild to moderate atopic dermatitis in children and adults aged 2 years and above in China Topical prescription drugs. Criborone is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme involved in controlling the activity of inflammatory cells. PDE4 participates in IL-4/5 in inflammatory cells by controlling the degradation of cyclic adenosine monophosphate. The production of inflammatory factors such as /10/13 and prostaglandin PGE2 plays a role by inhibiting the activity of PDE4 and improves the body's inflammatory response. Clinical studies have shown that 28-day treatment with criborole resulted in significant remission, complete or almost complete resolution of the rash compared with placebo in patients 2-79 years of age with mild to moderate atopic dermatitis. In 2017, the sales of criborole were US$67 million; in 2018, the global sales of criborole were US$147 million, with a growth rate of 119.40%, which brought new hope to many patients with atopic dermatitis.

    Use:

    AN2728 has shown potent activity in vivo and in vitro, and the anti-inflammatory properties of AN2728 are being investigated. Also used as pharmaceutical intermediates. Biologically active Crisaborole (AN2728) is a selective small molecule PDE4 inhibitor with broad-spectrum anti-inflammatory activity.

    
    

    
    

    
    

     
    
    
    
    
  • 
  • 
  • 
  
  

Q1: What's your MOQ?
A:It depends on different products,we can accept sample order or provide free sample for your test.

Q2:How about delivery leadtime?
A:Delivery lead time: About 3-5 days after payment confirmed. (Chinese holiday not included)

Q3: Is there a discount?
A:Different quantity has different discount.

Q4:How to start orders or make payments?
A:Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T.

Q5: How do you treat quality complaint?
A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.

Q6. We don't know you at all, how can we trust you?
A: You are always warm welcomed to visit us at any time. Commitment is the No.1 Point of our Enterprise's Value.

Q7.Do you test all your goods before delivery?
A:Yes, we have 100% test before delivery,International Authorized Third-Party Test for the products if you need are highly welcomed.